新闻
BLPH
--
0.00%
--
Bellerophon将出席HC Wainwright全球生命科学会议
WARREN, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH)...
GlobeNewswire · 6天前
[2020-2027] AMR吸入一氧化氮市场至11.8亿美元,复合年增长率为8.1%:
GlobeNewswire · 02/17 14:30
全球吸入一氧化氮(NO)输送系统市场Covid-19对2021年医疗保健行业的影响分析,规模,趋势,增长,份额,业务,关键参与者,合并,统计,竞争态势以及到2028年的区域预测
Feb 16, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Sector Global Analysis By Covid-19 Impact On, Size,...
The Express Wire · 02/16 05:20
Bellerophon(BLPH)获得美信集团的买入评级
In a report issued on March 26, Jason McCarthy from Maxim Group maintained a Buy rating on Bellerophon (BLPH), with a price target of $30.00. The
SmarterAnalyst · 02/09 09:08
临床试验市场规模估计,增长见识和预测2021年至2030年
Market Insight Reports · 02/04 07:08
重建网市场| 2021年COVID-19影响规模预测(按规模,增长率,趋势,份额,商业见解和2026年全球医疗保健行业展望)
Feb 02, 2021 (The Expresswire) -- Reconstruction Mesh Market | 2021 Healthcare Industry Post COVID-19 Analysis By Size, Business Growth, Share, New Trends,...
The Express Wire · 02/02 05:06
吸入一氧化氮(NO)输送系统市场2021年COVID-19影响规模预测(按规模,增长率,趋势,份额,商业见解和2026年全球医疗保健行业展望)
Feb 01, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Industry Post COVID-19 Analysis By Size, Business...
The Express Wire · 02/02 04:53
Global Nitric Oxide Therapy System Market 2020 Industry Overview, Competition by Manufacturers, Production Capacity by Region, Forecast by 2025
Jan 20, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has newly published research study entitled Global Nitric Oxide Therapy System Market 2020...
CDN Newswire · 01/21 02:08
Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Industry COVID-19 Impact Forecast By Size, Growth, Share Estimation, Business, And Global Trends Analysis To 2026
Jan 18, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 COVID-19 Impact On Healthcare Industry Size, Growth Rate,...
The Express Wire · 01/18 07:07
8-K: Bellerophon Therapeutics, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/12 05:50
生物技术的未来一周(12月27日至1月2日):数据发布,监管备案以转移库存
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K. The news flow of the week comprised mixed clinical trial readouts, COVID-19 drug and vaccine announcements, a few M&A announcements and a small-ticket IPO.
Benzinga · 2020/12/26 14:15
Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide
Toward the end of trading Monday, the Dow traded up 0.89% to 29,522.86 while the NASDAQ rose 0.08% to 11,864.80. The S&P also rose, gaining 0.37% to 3,570.63.
Benzinga · 2020/11/23 19:35
Mid-Day Market Update: Nasdaq Edges Lower; DPW Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.53% to 29,417.20 while the NASDAQ fell 0.19% to 11,832.26. The S&P also rose, gaining 0.07% to 3,559.94.
Benzinga · 2020/11/23 17:17
Mid-Morning Market Update: Markets Open Higher; AstraZeneca Covid-19 Vaccine Shows Up To 90% Efficacy In Late-Stage Trials
Following the market opening Monday, the Dow traded up 0.61% to 29,442.35 while the NASDAQ rose 0.12% to 11,868.79. The S&P also rose, gaining 0.38% to 3,571.09.
Benzinga · 2020/11/23 15:41
Bellerophon Therapeutics Puts COViNOX Study Of INOpulse For COVID-19 On Clinical Hold
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing
Benzinga · 2020/11/23 13:32
Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
finviz · 2020/11/11 12:30
Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates
finviz · 2020/11/05 14:05
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
finviz · 2020/11/05 12:30
Bellerophon To Present Results From Phase 2 iNO-PF Study Of INOpulse For Treatment Of Fibrotic Interstitial Lung Disease At Upcoming Scientific Conferences
Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) --
Benzinga · 2020/10/29 12:41
Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences
finviz · 2020/10/29 12:30
微牛提供丰富的实时BLPH股票新闻,让你可以通过多个平台了解BLPH股票行情最新动态,这些免费的柏勒罗丰治疗新闻可以帮助你做出明智投资。
BLPH 简况
Bellerophon Therapeutics, Inc.是一家临床阶段的治疗公司。该公司致力于开发满足心肺疾病医疗需求的药物和设备。该公司致力于开发治疗肺动脉高压(PH)的一氧化氮疗法,该疗法使用INOpulse输血系统,其中肺动脉高压(PAH)为主要指标。INOpulse设备具有在呼吸开始时定时产生短暂靶向脉冲一氧化氮的机制,以将一氧化氮递送到肺泡,这一机制最小化治疗所需药物量。该公司的另一个项目BCM是一种致力于预防伴随ST段抬高型心肌梗死(STEMI)的充血性心力衰竭的医疗设备,STEMI是一种严重的心脏病发作。该公司的BCM正处于临床试验PRESERVATION第一阶段。